Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall
By Bhanvi Satija Dec 15 (Reuters) – French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis drug and reported disappointing results from a late-stage study, sending shares of the company down 2%. Shares initially fell over 5% to the bottom of the SBF 120 index of …
Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall Read More »









